Advertisement
UK markets open in 1 hour 45 minutes

  • NIKKEI 225

    38,064.30
    +102.50 (+0.27%)
     

  • HANG SENG

    16,457.08
    +205.24 (+1.26%)
     

  • CRUDE OIL

    82.83
    +0.14 (+0.17%)
     

  • GOLD FUTURES

    2,390.60
    +2.20 (+0.09%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • Bitcoin GBP

    49,440.20
    -2,100.81 (-4.08%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     

  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     
Money:

5 ways to get help with childcare costs

Childcare is eye-wateringly expensive, here are some ways to save money

AstraZeneca's Lynparza fails in gastric cancer combination test

Reuters - UK Focus

LONDON, May 18 (Reuters) - AstraZeneca (NYSE: AZN - news) 's recently approved ovarian cancer drug Lynparza failed to increase overall survival significantly when given with chemotherapy to patients with gastric cancer in a late-stage trial, the drugmaker said on Wednesday.

The news is a setback for the British drugmaker, which reported positive results with an experimental acute asthma drug on Tuesday, although the result may have limited read-across for Lynparza in other cancer settings.

AstraZeneca said it was disappointed, but noted this particular trial was unusual in using a low dose and combining Lynparza with a standard chemotherapy.

The company has high hopes for Lynparza, which is central to its goal of building a portfolio of compounds targeting DNA damage response (DDR (NYSE: DDR - news) ) mechanisms in cancer cells. (Reporting by Ben Hirschler; Editing by Mark Potter)